GlassScriptPhysician profile
Darryl Elefan
NPI 1891927182
$1,686.72
in general payments reported to CMS, 2019-2025
15 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2022: $172 · 2023: $299 · 2024: $489 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Education: $15.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.19 |
| Education | $15.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $790.99 | 2019-2025 | Veltassa, Korsuva |
| Lilly USA, LLC | $232.90 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $217.73 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $89.72 | 2024-2025 | |
| Ardelyx, INC. | $80.85 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $72.42 | 2022-2025 | Lokelma |
| Nxstage Medical, INC. | $43.55 | 2025 | Liberty Select Cycler, Nxstage System One |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.10 | 2024 | Jardiance |
| Calliditas Therapeutics US INC. | $24.44 | 2024 | |
| Mallinckrodt Hospital Products INC. | $23.66 | 2025 | Acthar |
| Fresenius USA Marketing, INC. | $22.82 | 2025 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $20.75 | 2025 | |
| Cormedix INC. | $20.73 | 2025 | Defencath |
| Aurinia Pharma U.S., INC. | $13.61 | 2024 | Lupkynis |
| Travere Therapeutics, INC. | $3.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Elefan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.